| Literature DB >> 26637775 |
Abstract
The past 15 years have seen major leaps in our understanding of the molecular genetic mutations that act as drivers of acute myeloid leukemia (AML). Clinical trials of agents against specific mutant proteins, such as FLT3-internal tandem duplications (ITDs) and isocitrate dehydrogenase mutations (IDHs) are ongoing. This review discusses agents in clinical trials that target specific gene mutations and/or epigenetic targets.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26637775 DOI： 10.1182/asheducation-2015.1.579
Source DB: PubMed Journal: Hematology Am Soc Hematol Educ Program ISSN： 1520-4383